RTP Mobile Logo
Submitted by web@researchtop... on Tue, 07/24/2018 - 09:03
MTPHL118

 

Track 1: Case (Dr Favaro): A 34-year-old man with Stage IV Hodgkin lymphoma (HL) with bulky mediastinal lymph nodes and hepatic lesions
Track 2: Overview of HL
Track 3: Estimating risk of relapse after up-front therapy for advanced-stage HL
Track 4: Design, entry criteria and major efficacy and safety results from the Phase III ECHELON-1 trial evaluating brentuximab vedotin and doxorubicin/vinblastine/dacarbazine (AVD) versus AVD and bleomycin (ABVD) as front-line therapy for advanced-stage classical HL
Track 5: Risk-benefit ratio for administering brentuximab vedotin and AVD versus ABVD
Track 6: Incidence and management of bleomycin-associated pulmonary toxicity
Track 7: Clinical experience with brentuximab vedotin-associated peripheral neuropathy
Track 8: Implications of the ECHELON-1 trial results and recent FDA approval of brentuximab vedotin and chemotherapy as front-line therapy for advanced-stage classical HL
Track 9: Activity and duration of response with anti-PD-1/PD-L1 antibodies for advanced HL
Track 10: Case (Dr Lamar): A 22-year-old man with night sweats and a 10-cm neck mass who is diagnosed with HL
Track 11: Use of radiation therapy in HL
Track 12: Brentuximab vedotin and AVD followed by radiation therapy for unfavorable-risk early-stage HL
Track 13: BREACH: Results of a Phase II trial evaluating PET-based response after 2 cycles of brentuximab vedotin and AVD as first-line therapy for unfavorable-risk early-stage HL
Track 14: AETHERA: Study design and efficacy and safety of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in patients with HL at high risk of relapse
Track 15: Therapeutic options for salvage therapy
Track 16: Brentuximab vedotin with nivolumab for relapsed/refractory (R/R) HL
Track 17: Approach to patients with disease progression on front-line brentuximab vedotin and AVD
Track 18: Implications of inaccurate or misclassified HL diagnoses
Track 19: Case (Dr Mahajan): A 34-year-old woman with Stage IV HL achieves a partial response to nivolumab after experiencing disease progression through several lines of therapy
Track 20: Biology of HL and rationale for the response to immune checkpoint inhibitors
Track 21: Analysis of patients with cancer for CD274 (PD-L1) amplification: Implications for treatment with immune checkpoint blockade
Track 22: Clinical experience with and management of checkpoint inhibitor-related pulmonary side effects
Track 23: Case (Dr Favaro): A 43-year-old woman undergoes a median sternotomy for a suspected thymoma and is diagnosed with nodular sclerosing HL
Track 24: Case (Dr Lamar): An 83-year-old woman with Stage III HL receives 6 cycles of ABVD
Track 25: Case (Dr Lamar): A 60-year-old man with Stage IV HL and multiple comorbidities
Track 26: Response-adapted approach to administering brentuximab vedotin and AVD
Track 27: Use of growth factor support with brentuximab vedotin and AVD
Track 28: Case (Dr Mahajan): A 32-year-old woman with Stage IIA HL initially treated with 6 cycles of ABVD
Track 29: Response to brentuximab vedotin in a patient with disease relapse 2 years after ASCT
Track 30: Prognostic significance of baseline metabolic tumor volume in R/R HL
Track 31: Cost and value of brentuximab vedotin for patients on the ECHELON-1 study
Track 32: Perspectives on the use of follow-up imaging and surveillance
Track 33: Forecast on the future treatment of HL
 
FACULTY
 
John Kuruvilla, MD
Hematologist, Princess Margaret Cancer Centre
Associate Professor of Medicine
University of Toronto
Toronto, Ontario
 
Craig H Moskowitz, MD
Physician in Chief
Oncology Service Line
Sylvester Comprehensive Cancer Center
Professor
Department of Medicine
Miami, Florida
 
COMMUNITY ONCOLOGISTS
 
Justin P Favaro, MD, PhD
Oncology Specialists of Charlotte PA
Charlotte, North Carolina
 
Zanetta Lamar, MD
Assistant Professor, Hematology and Oncology
Maya Angelou Center for Health Equity
Redox Biology and Medicine Center
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
 
Neeraj Mahajan, MD
Hematology and Oncology
Assistant Clinical Professor, Medicine
CWRU School of Medicine
UH Parma Medical Center
UH Seidman Cancer Center
Parma, Ohio
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida